Platelets, Chromogranin A, and C-Reactive Protein Predict Therapy Failure of Metastatic Hormone-Sensitive Prostate...

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Androgen deprivation therapy (ADT) is standard for hormone-sensitive prostate cancer (HSPC).
• Androgen receptor pathway inhibitors (ARPIs) treat castration-resistant prostate cancer (CRPC).
• Combined ADT and ARPIs are now used for metastatic HSPC, necessitating new predictive markers.

Purpose of the Study:

• To identify novel plasma-based biomarkers for predicting treatment failure in prostate cancer.
• To evaluate miR-375 expression, AR gene amplification, and other clinical markers in HSPC and CRPC patients.
• To guide therapeutic decisions and monitor treatment response in advanced prostate cancer.

Main Methods:

• Plasma samples from 140 patients (72 metastatic HSPC, 68 CRPC) were analyzed before ARPI therapy.
• Digital PCR assessed AR gene amplification; quantitative PCR measured miR-375 expression.
• Evaluated 16 clinical markers including PSA, CGA, ALP, LDH, CRP, lymphocyte-to-monocyte ratio, and platelet count.

Main Results:

• In CRPC patients, miR-375 expression and lymphocyte-to-monocyte ratio independently predicted ARPI therapy failure.
• In HSPC patients, platelet count, CRP, and CGA independently predicted failure of combined ADT and ARPI therapy.
• AR gene amplification was also assessed as a potential marker.

Conclusions:

• miR-375 and lymphocyte-to-monocyte ratio are promising negative predictors of ARPI failure in CRPC.
• Platelet count, CRP, and CGA are valuable negative predictors for combined therapy failure in HSPC.
• These biomarkers can aid in monitoring disease progression and optimizing treatment strategies for prostate cancer.